Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205338 | 0.94 | GSK3B (0.63) | GSK3BPTPN1ALDH1A1PLK1SMN1; SMN2 | |
| SCHEMBL11705272 | 0.83 | THRA (0.65) | GSK3BPTPN1ALDH1A1PLK1SMN1; SMN2 | |
| SCHEMBL2153706 | 0.83 | L3MBTL1 (0.62) | GSK3BPTPN1ALDH1A1PLK1L3MBTL1 | |
| SCHEMBL205280 | 0.83 | GSK3B (0.80) | GSK3BPTPN1 | |
| SCHEMBL1687863 | 0.82 | ALDH1A1 (0.64) | ALDH1A1PLK1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL30089549 | 0.82 | ALDH1A1 (0.64) | ALDH1A1PLK1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL9237039 | 0.82 | GSK3B (0.64) | GSK3BPTPN1ALDH1A1THRATHRB | |
| SCHEMBL6816324 | 0.82 | GSK3B (0.64) | GSK3BPTPN1KMT2A | |
| SCHEMBL4866611 | 0.82 | ALDH1A1 (0.64) | ALDH1A1PLK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3011724 | 0.80 | THRA (0.66) | GSK3BPTPN1ALDH1A1PLK1THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1013444-B | PROCESS FOR THE PREPARATION OF A NOVEL CLASS OF HYPOGLYCEMIC AGENTS | LILLY CO ELI (US) | 1991-08-07 | — | — | CN | claimed |
| EP-4232448-B1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| EP-3956323-B1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | Halo Therapeutics Ltd (GB) | 2025-03-05 | — | — | EP | disclosed |
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | Halo Therapeutics Ltd (GB) | 2024-05-16 | — | — | US | disclosed |
| CN-117683026-A | 3-tetrahydrofuran chromone compound and diastereoisomeric divergent preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2024-03-12 | — | — | CN | disclosed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | GBIOTECH S.À.R.L. (CH) | 2022-09-01 | — | — | US | disclosed |
| US-4711899-A | 2-(4-benzoyl-1-piperidyl)-1-phenylalkanol derivatives | SYNTHELABO (FR) | 1987-12-08 | — | — | US | disclosed |
| US-4683312-A | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| US-4609670-A | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY (US) | 1986-09-02 | — | — | US | disclosed |
| EP-0182533-A2 | 3-(2-Aryl-2-oxoethyl)-imidazolium salts as hypoglycemic agents | ELI LILLY AND COMPANY (US) | 1986-05-28 | — | — | EP | disclosed |
| US-4097580-A | FUNGICIDES, BACTERICIDES, VIRICIDES | UNIROYAL, INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4059637-A | COUNTERCURRENT MULTISTAGE SOLVENT EXTRACTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-11-22 | — | — | US | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4004018-A | FUNGICIDES, BACTERICIDES, VIRICIDES | UNIROYAL INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3988375-A | HERBICIDES | MONSANTO COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | GSK3B 1686/4885PTPN1 3379/4885ALDH1A1 4445/4885 |
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | FFAR1, FFAR2, FFAR3 | GSK3B 4031/4885PTPN1 991/4885ALDH1A1 1767/4885 |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | FFAR2, FFAR1, FFAR3 | GSK3B 1838/4885PTPN1 1857/4885ALDH1A1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.